Endpoints News ٢ أبريل ٢٠٢٦ Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer
Endpoints News ٢ أبريل ٢٠٢٦ Eli Lilly's chief technology officer retires after 35 years; Astellas strategy exec resigns
Endpoints News ١ أبريل ٢٠٢٦ Lilly wins approval of anti-obesity pill orforglipron, setting up new battle with Novo
Endpoints News ٢٠ مارس ٢٠٢٦ UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
Endpoints News ١٩ مارس ٢٠٢٦ Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
Endpoints News ١٢ مارس ٢٠٢٦ Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News ١١ مارس ٢٠٢٦ Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Endpoints News ٦ مارس ٢٠٢٦ Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News ٢٦ فبراير ٢٠٢٦ Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Endpoints News ٢٤ فبراير ٢٠٢٦ Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
Endpoints News ٢٣ فبراير ٢٠٢٦ Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial